Candel Therapeutics, Inc.
CADL · XNASCIK 1841387fmd_1QZBZYN0PFW23QM8ZA1V10CWTDManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | – | – | – |
| Research and development | 9 | 15 | 21 | 25 | 19 | 30 |
| Total operating expenses | 14 | 26 | 35 | 38 | 33 | 48 |
| Compensation and benefits | – | – | – | 8 | 7 | 8 |
| Operating income | (14) | (26) | (35) | (38) | (33) | (48) |
| Interest expense | – | – | 2 | (3) | 2 | 2 |
| Interest and investment income | – | – | 1 | 2 | 1 | 4 |
| Other non-operating income (expense) | (4) | (10) | 16 | 0 | (22) | 10 |
| Income before taxes | – | – | – | – | (55) | (38) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (55) | (38) |
| Net income | (18) | (36) | (19) | (38) | (55) | (38) |